These findings suggest both the application of NEDD4L as a predictive biomarker for MM patients’ bortezomib response, as well as the development of NEDD4L activators in combination with bortezomib and autophagy regulators as a novel therapeutic approach for MM. Here, NEDD4L is linked to Miyoshi myopathy.